ClinicalTrials.gg
SuspendedNCT02962661Updated Nov 2, 2026

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

A Phase 1 interventional study of Best Practice and Laboratory Biomarker Analysis in Cardiomyopathy, Heart Failure and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center. Suspended at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by M.D. Anderson Cancer Center · Phase 1, Interventional, and Treatment

How we know

Why this study was suspended
PI Request
Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.

Planned enrollment
48th of 132
72 · median 42
Started
2020
with 6 others
Phase 1
18 of 231
5 open now
Registered
131st of 231
by date

Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 48th largest by planned enrollment of the 132 interventional ones that give a count, is one of 7 that started in 2020, is one of 18 in phase 1, and was the 131st registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Cardiomyopathies with a site in United States, or all of them as a file.
02

Study summary

This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.

Read the detailed description

PRIMARY OBJECTIVE:

I. To demonstrate the safety of allogeneic human mesenchymal stem cells (hMSCs) administered by intravenous infusion and transendocardial injection in patients with left ventricular (LV) dysfunction and heart failure secondary to chemotherapy with anthracyclines.

SECONDARY OBJECTIVE:

I. To demonstrate the efficacy of allogeneic hMSCs administered by intravenous infusion and transendocardial injection in patients with left ventricular dysfunction (left ventricular ejection fraction [LVEF] \< 40%) and heart failure secondary to treatment with anthracyclines.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive hMSCs intravenously (IV) over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.

ARM III: Patients receive standard of care treatment for heart failure.

After completion of study treatment, patients are followed up periodically.

03

Conditions studied

  • Cardiomyopathy
  • Heart Failure
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with \</= 40% documented from treatment with anthracyclines for any at any dose at any time without evidence of other causes of cardiomyopathy.
  2. Age >/= 18 and \</= 90 years of age. English and non-English speaking patients are eligible.
  3. Documented class I, II and III.
  4. For patients who have received trastuzumab: Persistent LV dysfunction must be present 90 days after discontinuation of trastuzumab.
  5. Able to perform 6 minute walk test.
  6. Been treated with appropriate maximal medical therapy for heart failure.
  7. Patient or legally authorized representative able to sign .

Exclusion criteria

Exclusion Criteria:

  1. Evidence of Ischemic Heart Disease as determined by study cardiologist.
  2. Significant Valvular Disease. (AS with AVA \<1.5 and severe AR and MR)
  3. History of Familial Cardiomyopathy.
  4. Recent documented myocarditis within 2 months of enrollment.
  5. History of Infiltrative cardiomyopathy or restrictive cardiomyopathy.
  6. Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram.
  7. Liver function tests > 3 x .
  8. class IV heart failure.
  9. Inotropic dependence.
  10. Unstable or life-threatening arrhythmia.
  11. For patients not on anticoagulants, >1.5
  12. Mechanical or Bioprosthetic heart valve.
  13. Cardiogenic shock.
  14. Breastfeeding and/or pregnant women.
  15. disorders on current therapy.
  16. Active infection not responding to appropriate therapy as determined by Study Chair.
  17. Trastuzumab treatment within the last 3 months.
  18. Automatic implantable cardioverter defibrillator (AICD) placement within the last 30 days.
  19. AICD firing within the last 30 days.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Arm I (hMSCs IV)

    Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.

    Other: Best Practice · Other: Laboratory Biomarker Analysis · Drug: Mesenchymal Stem Cell Transplantation

  • Experimental
    Arm II (hMSCs transendocardially)

    Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.

    Other: Best Practice · Other: Laboratory Biomarker Analysis · Drug: Mesenchymal Stem Cell Transplantation

  • Active comparator
    Arm III (standard of care)

    Patients receive standard of care treatment for heart failure.

    Other: Best Practice · Other: Laboratory Biomarker Analysis

Interventions

  • OtherBest Practice

    Given standard of care

    Also known as: standard of care, standard therapy

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • DrugMesenchymal Stem Cell Transplantation

    Given IV

  • DrugMesenchymal Stem Cell Transplantation

    Given transendocardially

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Statistical analyses of safety will be descriptive.

    Time frame: Up to 6 months

  2. Change in left ventricular ejection fraction (LVEF)

    The comparison will be between the two groups of patients.

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Change in improvement of left ventricular (LV) systolic function as assessed by LVEF

    As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p \< .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

    Time frame: Baseline up to 6 months

  2. LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography

    As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p \< .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

    Time frame: Up to 6 months

  3. Cardiac death

    As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p \< .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

    Time frame: Up to 6 months

  4. Re-hospitalization after heart failure

    As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p \< .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

    Time frame: Up to 6 months

  5. Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing

    As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p \< .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

    Time frame: Up to 6 months

  6. Nonfatal myocardial infarction

    As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p \< .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

    Time frame: Up to 6 months

  7. Revascularization

    As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p \< .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

    Time frame: Up to 6 months

07

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2020 (actual). Primary completion is estimated for Jul 2027, 84 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2016
First posted
Nov 11, 2016
StartActual
Jul 18, 2020
Primary completionEst.
Jul 30, 2027was Jul 2026
CompletionEst.
Jul 30, 2027was Jul 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 30, 2026→Jul 30, 2027
Nov 2, 2026
Study completion
Jul 30, 2026→Jul 30, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Jul 30, 2026→Jul 30, 2027
    Study completion Jul 30, 2026→Jul 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02962661
Responsible party
Sponsor
First posted
Nov 11, 2016
Start date
Jul 18, 2020
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Paul Lin, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion